San Diego, CA -- (SBWIRE) -- 07/25/2016 -- An investor, who purchased NASDAQ:INSM share, filed a lawsuit in New Jersey over alleged violations of Federal Securities Laws by Insmed Incorporated in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Insmed Incorporated (NASDAQ:INSM) have certain options and for certain investors are short and strict deadlines running. Deadline: September 13, 2016. NASDAQ:INSM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The plaintiff alleges on behalf of purchasers of Insmed Incorporated (NASDAQ:INSM) common shares between March 18, 2013 and June 8, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 18, 2013 and June 8, 2016 defendants issued allegedly false and misleading statements to investors and/or failed to disclose that the data on which Insmed's European marketing authorization application for Arikayce, Insmed's lead product candidate, relied was not likely to support approval by the European Medicines Agency ("EMA") for the treatment of nontuberculous mycobacteria ("NTM") lung disease, that Arikayce's approval by the EMA for the treatment of NTM lung disease and subsequent commercialization in Europe were thus less likely and/or imminent than Insmed had led investors to believe, and that as a result, defendants' statements about Insmed's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.. When the true details entered the market, the lawsuit claims that investors suffered damages.

On June 8, 2016, post-market, Insmed Incorporated announced that it had withdrawn a European marketing application submitted to the European Medicines Agency for its lung disease drug Arikayce. Insmed Incorporated stated that the marketing application was based on data from a mid-stage clinical study that didn't support enough evidence for an approval from the European Medicines Agency. Insmed Incorporated stated that the Company will resubmit the application when data is available from a later study.

Shares of Insmed Incorporated (NASDAQ:INSM) declined to $9.95 per share on June 9, 2016.

On July 22, 2016, NASDAQ:INSM shares closed at $11.06 per share.

Those who purchased shares of Insmed Incorporated have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com